What smart money is saying about Mettler-Toledo International Inc.
2 funds in our archive have pitched Mettler-Toledo International Inc. — most recently Baron Health Care Fund in June 2026.
Mettler-Toledo International Inc. (MTD) is a global enterprise dedicated to the production and provision of precision instruments and related services. The company's operations are strategically organized across five geographical divisions: its domestic U.S. market, Swiss operations, Western European activities, Chinese operations, and an 'Other' segment covering remaining territories. Their extensive product portfolio serves diverse scientific and industrial needs. Within the laboratory sphere, Mettler-Toledo supplies a comprehensive array of equipment, including high-precision balances, advanced liquid handling systems (such as pipetting solutions), automated laboratory reactors, titrators, pH meters, sensors and analyzers for process analytics, instruments for evaluating physical properties, thermal analysis systems, and various other analytical tools. These hardware offerings are complemented by LabX, their proprietary software platform designed for managing and analyzing instrument-generated data. For industrial applications, the company offers robust weighing instruments with associated terminals, automated systems for dimensional measurement and data capture, heavy-duty vehicle scales, specialized industrial software, and a full suite of product inspection technologies. This includes metal detectors, X-ray inspection systems, checkweighers, camera-based imaging equipment, and solutions for track-and-trace. Additionally, Mettler-Toledo provides sophisticated retail weighing solutions, encompassing networked scales and accompanying software, standalone scales, and automated packaging and labeling systems specifically tailored for fresh food items. The company caters to a wide spectrum of clients, including the life sciences sector, independent research organizations, testing laboratories, food and beverage manufacturers, food retailers, chemical, specialty chemical, and cosmetics companies, transportation and logistics firms, metals and electronics industries, and the academic community. Sales and support are conducted through both a direct sales force and an established network of indirect distribution channels. Mettler-Toledo International Inc. was founded in 1991 and is headquartered in Columbus, Ohio.
Get an email when a fund writes about it
Position history
Every position in Mettler-Toledo International Inc. on record in the archive was reported in Q2 2026, across 3 fund letters — 2 opened or added to the position, 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 3 | 2 | 1 | 2 |
Fund activity · 3 positions · 3 moves
- ExitedFundsmith Equity FundJune 2026
“We exited or have started exiting: Atlas Copco, Coloplast, Essilor Luxottica, Intuit, LVMH, Magnum Ice Cream, Mettler-Toledo, Nike, Novo Nordisk, Otis, Unilever, Wolters Kluwer, and Zoetis.”
Mettler-Toledo International Inc. - June 2026
“Top net purchases for the quarter Quarter End Market Cap ($B) Net Amount Purchased ($M) UnitedHealth Group Incorporated 377.5 3.8 Elevance Health, Inc. 84.0 1.9 Revolution Medicines, Inc. 39.8 1.4 Mettler-Toledo International Inc. 25.8 1.4 Sartorius Stedim Biotech S.A. 20.2 0.9 We re-established positions in two previously owned managed care companies, UnitedHealth Group Incorporated and Elevance Health, Inc . Both companies manage diversified portfolios, providing insurance and health care services to Commercial, Exchange, Medicaid and Medicare Advantage members. We believe that the insurance cycle is turning more favorable for these companies, particularly in their Medicare Advantage businesses. After several years of elevated utilization trends, inadequate reimbursement, and regulatory challenges coupled with aggressive pricing to drive share gains, which drove operating margins to depressed levels, UnitedHealth and Elevance have exited unprofitable Medicare Advantage markets and products, right-sized benefits, and are now in the process of rebuilding profitability. We further think that the application of AI will enable them to take a significant bite out of administrative costs as well. Finally, we believe that the earnings power of both companies is well above current levels assuming they can approach their long-term target margins over the next few years. If we further assume a reasonable multiple on future earnings power, we believe there is substantial upside in both stocks. We added to our position in Revolution Medicines, Inc. , a biotechnology company developing medicines to treat cancers driven by rat sarcoma (RAS) mutations. The company estimates there are 190,000 new cancer diagnoses each year in the U.S. that are driven by RAS mutations, including approximately 60,000 patients with non-small cell lung cancer, 75,000 patients with colorectal cancer, and 56,000 patients with pancreatic cancer. In April, the company released topline results from its RASolute 302 trial in which patients with advanced pancreatic cancer who received the company’s medicine Daraxonrasib in the second line had a median overall survival of 13.2 months compared to 6.7 months for the patients who received chemotherapy. Subsequently at the annual meeting of the American Society of Clinical Oncology (ASCO), the clinical trial investigators presented the full data which confirmed the groundbreaking results. In this patient population, Daraxonrasib reduced the risk of death by 60% compared with chemotherapy. The presentation at ASCO received a standing ovation, which is rare in oncology and even rarer in pancreatic cancer. Daraxonrasib represents the first major advance in pancreatic cancer in over 30 years. Also, during the quarter, the company announced encouraging data from two earlier stage trials of Daraxonrasib in first-line (previously untreated) pancreatic cancer patients. The company is also studying Daraxonrasib in non-small cell lung cancer and other solid tumors and has other drugs in development, including combination therapies, for each of these cancers. When Daraxonrasib is FDA approved later this year, we think the demand will be strong, leading to rapid adoption. We think the company’s leadership position in this category will be difficult to displace, and ultimately, we think the company could generate peak sales over $20 billion. We added to our position in Mettler-Toledo International Inc ., a company we have owned in the Fund since inception.”
Mettler-Toledo International Inc. - New positionWeitz Investments Multi Cap Equity FundJune 2026
“We have long admired Mettler’s business and purchased a small position during a brief period of price dislocation during the quarter.”
Mettler-Toledo International Inc.
Fund coverage · 2 theses
- Baron Health Care FundJune 2026
Mettler-Toledo supplies precision instruments and services, supported by strong competitive advantages, a long growth record, and attractive valuation.
Read the full thesis Mettler-Toledo is a precision measurement supplier with a specialized sales and service organization that supports long-term customer relationships.
Read the full thesis
Read every full thesis on Mettler-Toledo International Inc.
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→